Why the study?
To describe lipid abnormalities in diabetes, when they occur, and the evidence base for lipid management with established and new drugs to prevent complications, as well as managing statin intolerance.
Statins remain first-line therapy for lipid management in diabetes, with emerging evidence supporting the use of ezetimibe and PCSK9 inhibitors as add-on therapies, and highlighting a need for earlier intervention in younger patients.
PURPOSE OF REVIEW: To describe lipid abnormalities in diabetes, when they occur and the evidence base for lipid management with established and new drugs to prevent diabetes complications. We also discuss how to manage statin intolerance. RECENT FINDINGS: Statins remain first-line therapy in patients with diabetes, though newer therapies to reduce LDL-C have emerged, including ezetimibe as an add-on therapy to statins, and injectable PCSK9 inhibitors, both of which are safe and effective in diabetes. Emerging evidence suggests a need to consider lipid-lowering therapies more often in younger patients with both type 1 and type 2 diabetes. Statins remain the cornerstone of lipid management in diabetes but other options are increasing. There is also now evidence for better managing apparent statin intolerance. Notably, younger patients lose the most life years from their diabetes, an observation that future guidelines need to consider.
No takes yet. Share an insight, caveat, or question.
Sillars et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: